Literature DB >> 25973127

ALK-rearranged squamous cell lung cancer: a case report.

Quan Zhang1, Jinghui Wang1, Shucai Zhang1.   

Abstract

ALK rearrangement is a very rare subset of squamous cell cancer of lung and the efficacy of crizotinib treatment for these patients is lack of data. Here we report a case with squamous cell cancer of lung that harbored the ALK rearrangement was given crizotinib in the second-line therapy. A 55-year-old female patient was diagnosed with squamous cell carcinoma of lung by bronchoscopy biopsy with stage IV. The patient was given two cycles of chemotherapy and the response was progressive disease. After failure to chemotherapy, genotype testing showed wild-type EGFR/KRAS and ALK rearrangement positive. The patient was administered with crizotinib and had a partial response, and the progression-free survival was 6 months. The side effects were tolerable.

Entities:  

Keywords:  ALK rearrangement; crizotinib; squamous cell carcinoma

Mesh：

Substances：

Year:  2015        PMID： 25973127      PMCID： PMC4396204     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN： 1936-2625


  11 in total

Review 1.  Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities.

Authors:  Pablo Perez-Moreno; Elisabeth Brambilla; Roman Thomas; Jean-Charles Soria
Journal:  Clin Cancer Res       Date:  2012-03-08       Impact factor: 12.531

2.  [The Diagnosis and Treatment Guideline of Chinese Patients with EGFR Mutation and ALK Fusion Gene-Positive Non-Small Cell Lung Cancer (2013 Version)].

Authors: 
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2013-06

3.  Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.

Authors:  Jinghui Wang; Yujie Dong; Yiran Cai; Lijuan Zhou; Shafei Wu; Guimei Liu; Dan Su; Xi Li; Na Qin; Jingying Nong; Hongyan Jia; Quan Zhang; Jing Mu; Xuan Zeng; Haiqing Zhang; Shucai Zhang; Zongde Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-18       Impact factor: 4.553

4.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Authors:  Alice T Shaw; Beow Y Yeap; Mari Mino-Kenudson; Subba R Digumarthy; Daniel B Costa; Rebecca S Heist; Benjamin Solomon; Hannah Stubbs; Sonal Admane; Ultan McDermott; Jeffrey Settleman; Susumu Kobayashi; Eugene J Mark; Scott J Rodig; Lucian R Chirieac; Eunice L Kwak; Thomas J Lynch; A John Iafrate
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

5.  EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.

Authors:  Kentaro Inamura; Kengo Takeuchi; Yuki Togashi; Satoko Hatano; Hironori Ninomiya; Noriko Motoi; Ming-yon Mun; Yukinori Sakao; Sakae Okumura; Ken Nakagawa; Manabu Soda; Young Lim Choi; Hiroyuki Mano; Yuichi Ishikawa
Journal:  Mod Pathol       Date:  2009-02-20       Impact factor: 7.842

6.  Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.

Authors:  Xuchao Zhang; Shirley Zhang; Xuening Yang; Jinji Yang; Qing Zhou; Lucy Yin; Shejuan An; Jiaying Lin; Shiliang Chen; Zhi Xie; Mike Zhu; Xiaolin Zhang; Yi-long Wu
Journal:  Mol Cancer       Date:  2010-07-13       Impact factor: 27.401

7.  ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung.

Authors:  Anna Caliò; Alessia Nottegar; Eliana Gilioli; Emilio Bria; Sara Pilotto; Umberto Peretti; Stefania Kinspergher; Francesca Simionato; Serena Pedron; Sakari Knuutila; Giampaolo Tortora; Albino Eccher; Antonio Santo; Luca Tondulli; Giorgio Inghirami; Fabrizio Tabbò; Guido Martignoni; Marco Chilosi; Aldo Scarpa; Matteo Brunelli
Journal:  J Thorac Oncol       Date:  2014-05       Impact factor: 15.609

8.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962

9.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors:  D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316

10.  Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.

Authors:  Ying Li; Yongwen Li; Tong Yang; Sen Wei; Jing Wang; Min Wang; Yuli Wang; Qinghua Zhou; Hongyu Liu; Jun Chen
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240
View more
  9 in total

Review 1.  Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review.

Authors:  Bo Zhang; Yanwei Zhang; Jianlin Xu; Xueyan Zhang; Tianqing Chu; Shuyuan Wang; Jie Qian; Rong Qiao; Jun Lu; Lele Zhang; Baohui Han
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

2.  Anaplastic lymphoma kinase-positive squamous cell carcinoma of the lung: A case report.

Authors:  Yoko Yamamoto; Ken Kodama; Tomohiro Maniwa; Masashi Takeda; Hiroki Kishima
Journal:  Mol Clin Oncol       Date:  2016-04-26

Review 3.  Lung cancer in never smokers-the East Asian experience.

Authors:  Fei Zhou; Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2018-08

Review 4.  ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.

Authors:  Nobuaki Mamesaya; Kazuhisa Nakashima; Tateaki Naito; Takashi Nakajima; Masahiro Endo; Toshiaki Takahashi
Journal:  BMC Cancer       Date:  2017-07-06       Impact factor: 4.430

5.  Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review.

Authors:  Junko Watanabe; Shinsaku Togo; Issei Sumiyoshi; Yukiko Namba; Kentaro Suina; Takafumi Mizuno; Kotaro Kadoya; Hiroaki Motomura; Moe Iwai; Tetsutaro Nagaoka; Shinichi Sasaki; Takuo Hayashi; Toshimasa Uekusa; Kanae Abe; Yasuo Urata; Fuminori Sakurai; Hiroyuki Mizuguchi; Shunsuke Kato; Kazuhisa Takahashi
Journal:  Oncotarget       Date:  2018-05-08

6.  Multiline treatment of advanced squamous cell carcinoma of the lung: A case report and review of the literature.

Authors:  Xin Yang; Ping Peng; Li Zhang
Journal:  World J Clin Cases       Date:  2019-07-26       Impact factor: 1.337

7.  ALK-rearranged squamous cell carcinoma of the lung.

Authors:  Qiyi Meng; Yujie Dong; Hong Tao; Liang Shi; Li Tong; Junfang Tang; Shucai Zhang; Zhe Liu
Journal:  Thorac Cancer       Date:  2021-02-09       Impact factor: 3.500

8.  Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report.

Authors:  Shuluan Li; Pei Zhang; Tianyu Wang; Jie Wang; Jianchun Duan
Journal:  Thorac Cancer       Date:  2021-10-13       Impact factor: 3.500

9.  Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.

Authors:  Jun Shiihara; Fumiyoshi Ohyanagi; Hikari Amari; Minemichi Toda; Hiroki Tahara; Motoi Yuzawa; Yuki Maeda; Motoko Nomura; Yoshiko Mizushina; Yoshiaki Nagai; Hiromitsu Ohta; Yasuhiro Yamaguchi
Journal:  Thorac Cancer       Date:  2021-07-29       Impact factor: 3.500
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.